Insights into the role of maladaptive hexosamine biosynthesis and O-GlcNAcylation in development of diabetic cardiac complications

Pharmacological Research

Volumn 116, Issue , 2017, Pages 45-56

  Qin, Cheng Xue ^a,b   Sleaby, Rochelle ^a,b   Davidoff, Amy J ^c   Bell, James R ^b   De Blasio, Miles J ^a,b   Delbridge, Leanne M ^b   Chatham, John C ^d   Ritchie, Rebecca H ^a,b,e  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF NEW ENGLAND   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e MONASH UNIVERSITY   (Australia)

Author keywords

Cardiac remodeling; Diabetic cardiomyopathy; Diastolic function; Hyperglycemia; O GlcNAcylation

Indexed keywords

1,2 DIDEOXY 2' PROPYL ALPHA DEXTRO GLUCOPYRANOSE[2,1 DEXTRO]DELTA2' THIAZOLINE; 6 DIAZO 5 OXONORLEUCINE; ADRENERGIC RECEPTOR; ALLOXAN; AMINO N PHENYL CARBAMATE; AMINOTRANSFERASE; AZASERINE; BENZYL 2 ACETAMIDO 2 DEOXY ALPHA DEXTRO GALACTOPYRANOSIDE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM ION; ENZYME INHIBITOR; FRUCTOSE 6 PHOSPHATE; GLCNACSTATIN; GLUCOSAMINE; GLUTAMINE FRUCTOSE 6 PHOSPHATE AMINOTRANSFERASE; HEXOSAMINE; N ACETYLGLUCOSAMINE; QUINOLINONE 6 SULFONAMIDE; THIAMET G; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE N ACETYLGLUCOSAMINE;

ARTICLE; CALCIUM CURRENT; CARBOHYDRATE SYNTHESIS; CARDIAC MUSCLE CELL; DIABETIC CARDIOMYOPATHY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART HYPERTROPHY; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HUMAN; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; MOUSE MODEL; NONHUMAN; O GLCNACYLATION; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; UPREGULATION; ANIMAL; BIOSYNTHESIS; DIABETES MELLITUS; DIABETIC COMPLICATION; GLYCOSYLATION; HEART; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHIES; GLYCOSYLATION; HEART; HEXOSAMINES; HUMANS;

EID: 85008516879     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.12.016     Document Type: Article

References (191)

1. [1] Teo, C.F., Ingale, S., Wolfert, M.A., Elsayed, G.A., Not, L.G., Chatham, J.C., Wells, L., Boons, G.J., Glycopeptide-specific monoclonal antibodies suggest new roles for O-GlcNAc. Nat. Chem. Biol. 6:5 (2010), 338–343.
2. [2] Bugger, H., Abel, E.D., Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 57:4 (2014), 660–671.
3. [3] Huynh, K., Bernardo, B.C., McMullen, J.R., Ritchie, R.H., Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol. Ther. 142:3 (2014), 375–415.
4. [4] Rubler, S., Dlugash, J., Yuceoglu, Y.Z., Kumral, T., Branwood, A.W., Grishman, A., New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol. 30:6 (1972), 595–602.
5. [5] Ren, J., Gintant, G.A., Miller, R.E., Davidoff, A.J., High extracellular glucose impairs cardiac E-C coupling in a glycosylation-dependent manner. Am. J. Physiol. 273:6 Pt 2 (1997), H2876–2883.
6. [6] Brownlee, M., The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:6 (2005), 1615–1625.
7. [7] An, D., Rodrigues, B., Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 291:4 (2006), H1489–1506.
8. [8] Petrova, R., Yamamoto, Y., Muraki, K., Yonekura, H., Sakurai, S., Watanabe, T., Li, H., Takeuchi, M., Makita, Z., Kato, I., Takasawa, S., Okamoto, H., Imaizumi, Y., Yamamoto, H., Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J. Mol. Cell. Cardiol. 34:10 (2002), 1425–1431.
9. [9] Davidoff, A.J., Davidson, M.B., Carmody, M.W., Davis, M.E., Ren, J., Diabetic cardiomyocyte dysfunction and myocyte insulin resistance: role of glucose-induced PKC activity. Mol. Cell. Biochem. 262:1-2 (2004), 155–163.
10. [10] Huang, P., Ho, S.R., Wang, K., Roessler, B.C., Zhang, F., Hu, Y., Bowe, D.B., Kudlow, J.E., Paterson, A.J., Muscle-specific overexpression of NCOATGK, splice variant of O-GlcNAcase, induces skeletal muscle atrophy. Am. J. Physiol. Cell Physiol. 300:3 (2011), C456–465.
11. [11] Keembiyehetty, C., Love, D.C., Harwood, K.R., Gavrilova, O., Comly, M.E., Hanover, J.A., Conditional knock-out reveals a requirement for O-linked N-Acetylglucosaminase (O-GlcNAcase) in metabolic homeostasis. J. Biol. Chem. 290:11 (2015), 7097–7113.
12. [12] Hart, G.W., Housley, M.P., Slawson, C., Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature 446:7139 (2007), 1017–1022.
13. [13] Laczy, B., Hill, B.G., Wang, K., Paterson, A.J., White, C.R., Xing, D., Chen, Y.F., Darley-Usmar, V., Oparil, S., Chatham, J.C., Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system. Am. J. Physiol. Heart Circ. Physiol. 296:1 (2009), H13–28.
14. [14] Ngoh, G.A., Facundo, H.T., Zafir, A., Jones, S.P., O-GlcNAc signaling in the cardiovascular system. Circ. Res. 107:2 (2010), 171–185.
15. [15] Teo, C.F., Wollaston-Hayden, E.E., Wells, L., Hexosamine flux, the O-GlcNAc modification, and the development of insulin resistance in adipocytes. Mol. Cell Endocrinol. 318:1-2 (2010), 44–53.
16. [16] Marshall, S., Bacote, V., Traxinger, R.R., Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J. Biol. Chem. 266:8 (1991), 4706–4712.
17. [17] Cieniewski-Bernard, C., Mounier, Y., Michalski, J.C., Bastide B: O-GlcNAc level variations are associated with the development of skeletal muscle atrophy. J. Appl. Physiol. (1985) 100:5 (2006), 1499–1505.
18. [18] Broschat, K.O., Gorka, C., Page, J.D., Martin-Berger, C.L., Davies, M.S., Huang Hc, H.C., Gulve, E.A., Salsgiver, W.J., Kasten, T.P., Kinetic characterization of human glutamine-fructose-6-phosphate amidotransferase I: potent feedback inhibition by glucosamine 6-phosphate. J. Biol. Chem. 277:17 (2002), 14764–14770.
19. [19] Vercoutter-Edouart, A.S., Yazidi-Belkoura, I.E., Guinez, C., Baldini, S., Leturcq, M., Mortuaire, M., Mir, A.M., Steenackers, A., Dehennaut, V., Pierce, A., Lefebvre, T., Detection and identification of O-GlcNAcylated proteins by proteomic approaches. Proteomics 15:5–6 (2015), 1039–1050.
20. [20] Slawson, C., Copeland, R.J., Hart, G.W., O-GlcNAc signaling: a metabolic link between diabetes and cancer?. Trends Biochem. Sci. 35:10 (2010), 547–555.
21. [21] Zeidan, Q., Hart, G.W., The intersections between O-GlcNAcylation and phosphorylation: implications for multiple signaling pathways. J. Cell Sci. 123:Part 1 (2010), 13–22.
22. [22] Davidoff, A.J., Convergence of glucose- and fatty acid-induced abnormal myocardial excitation-contraction coupling and insulin signalling. Clin. Exp. Pharmacol. Physiol. 33:1–2 (2006), 152–158.
23. [23] Perspective, Rossetti L., Hexosamines and nutrient sensing. Endocrinology 141:6 (2000), 1922–1925.
24. [24] McClain, D.A., Hexosamines as mediators of nutrient sensing and regulation in diabetes. J. Diabetes Complications 16:1 (2002), 72–80.
25. [25] Wells, L., Vosseller, K., Hart, G.W., A role for N-acetylglucosamine as a nutrient sensor and mediator of insulin resistance. Cell Mol. Life Sci. 60:2 (2003), 222–228.
26. [26] Zachara, N.E., Hart, G.W., O-GlcNAc a sensor of cellular state: the role of nucleocytoplasmic glycosylation in modulating cellular function in response to nutrition and stress. Biochim. Biophys. Acta. 1673:1–2 (2004), 13–28.
27. [27] Ngoh, G.A., Jones, S.P., New insights into metabolic signaling and cell survival: the role of beta-O-linkage of N-acetylglucosamine. J. Pharmacol. Exp. Ther. 327:3 (2008), 602–609.
28. [28] Bond, M.R., Hanover, J.A., O-GlcNAc cycling: a link between metabolism and chronic disease. Ann. Rev. Nutr. 33 (2013), 205–229.
29. [29] Kim, E.J., Chemical arsenal for the study of O-GlcNAc. Molecules 16:3 (2011), 1987–2022.
30. [30] Hart, G.W., Slawson, C., Ramirez-Correa, G., Lagerlof, O., Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Ann. Rev. Biochem. 80 (2011), 825–858.
31. [31] Dassanayaka, S., Jones, S.P., O-GlcNAc and the cardiovascular system. Pharmacol. Ther. 142:1 (2014), 62–71.
32. [32] Torres, C.R., Hart, G.W., Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J. Biol. Chem. 259:5 (1984), 3308–3317.
33. [33] Banerjee, P.S., Ma, J., Hart, G.W., Diabetes-associated dysregulation of O-GlcNAcylation in rat cardiac mitochondria. Proc. Natl. Acad. Sci. U. S. A. 112:19 (2015), 6050–6055.
34. [34] Isono, T., O-GlcNAc-specific antibody CTD110.6 cross-reacts with N-GlcNAc2-modified proteins induced under glucose deprivation. PLoS One, 6(4), 2011, e18959.
35. [35] Greis, K.D., Hayes, B.K., Comer, F.I., Kirk, M., Barnes, S., Lowary, T.L., Hart, G.W., Selective detection and site-analysis of O-GlcNAc-modified glycopeptides by beta-elimination and tandem electrospray mass spectrometry. Anal. Biochem. 234:1 (1996), 38–49.
36. [36] Wells, L., Vosseller, K., Cole, R.N., Cronshaw, J.M., Matunis, M.J., Hart, G.W., Mapping sites of O-GlcNAc modification using affinity tags for serine and threonine post-translational modifications. Mol. Cell Proteomics 1:10 (2002), 791–804.
37. [37] Vosseller, K., Trinidad, J.C., Chalkley, R.J., Specht, C.G., Thalhammer, A., Lynn, A.J., Snedecor, J.O., Guan, S., Medzihradszky, K.F., Maltby, D.A., Schoepfer, R., Burlingame, A.L., O-linked N-acetylglucosamine proteomics of postsynaptic density preparations using lectin weak affinity chromatography and mass spectrometry. Mol. Cell Proteomics 5:5 (2006), 923–934.
38. [38] Wang, Z., Udeshi, N.D., O'Malley, M., Shabanowitz, J., Hunt, D.F., Hart, G.W., Enrichment and site mapping of O-linked N-acetylglucosamine by a combination of chemical/enzymatic tagging, photochemical cleavage, and electron transfer dissociation mass spectrometry. Mol. Cell. Proteomics 9:1 (2010), 153–160.
39. [39] Alfaro, J.F., Gong, C.X., Monroe, M.E., Aldrich, J.T., Clauss, T.R., Purvine, S.O., Wang, Z., Camp, D.G., 2nd Shabanowitz, J., Stanley, P., Hart, G.W., Hunt, D.F., Yang, F., Smith, R.D., Tandem mass spectrometry identifies many mouse brain O-GlcNAcylated proteins including EGF domain-specific O-GlcNAc transferase targets. Proc. Natl. Acad. Sci. U. S. A. 109:19 (2012), 7280–7285.
40. [40] Darley-Usmar, V.M., Ball, L.E., Chatham, J.C., Protein O-linked beta-N-acetylglucosamine: a novel effector of cardiomyocyte metabolism and function. J. Mol. Cell Cardiol 52:3 (2012), 538–549.
41. [41] Mikesh, L.M., Ueberheide, B., Chi, A., Coon, J.J., Syka, J.E., Shabanowitz, J., Hunt, D.F., The utility of ETD mass spectrometry in proteomic analysis. Biochim. Biophys. Acta 1764:12 (2006), 1811–1822.
42. [42] Virkamaki, A., Daniels, M.C., Hamalainen, S., Utriainen, T., McClain, D., Yki-Jarvinen, H., Activation of the hexosamine pathway by glucosamine in vivo induces insulin resistance in multiple insulin sensitive tissues. Endocrinology 138:6 (1997), 2501–2507.
43. [43] Liu, J., Pang, Y., Chang, T., Bounelis, P., Chatham, J.C., Marchase, R.B., Increased hexosamine biosynthesis and protein O-GlcNAc levels associated with myocardial protection against calcium paradox and ischemia. J. Mol. Cell Cardiol. 40:2 (2006), 303–312.
44. [44] Laczy, B., Fulop, N., Onay-Besikci, A., Des Rosiers, C., Chatham, J.C., Acute regulation of cardiac metabolism by the hexosamine biosynthesis pathway and protein O-GlcNAcylation. PLoS One, 6(4), 2011, e18417.
45. [45] Marshall, S., Nadeau, O., Yamasaki, K., Dynamic actions of glucose and glucosamine on hexosamine biosynthesis in isolated adipocytes: differential effects on glucosamine 6-phosphate, UDP-N-acetylglucosamine, and ATP levels. J. Biol. Chem. 279:34 (2004), 35313–35319.
46. [46] Oki, T., Yamazaki, K., Kuromitsu, J., Okada, M., Tanaka, I., cDNA cloning and mapping of a novel subtype of glutamine:fructose-6-phosphate amidotransferase (GFAT2) in human and mouse. Genomics 57:2 (1999), 227–234.
47. [47] DeHaven, J.E., Robinson, K.A., Nelson, B.A., Buse, M.G., A novel variant of glutamine: fructose-6-phosphate amidotransferase-1 (GFAT1) mRNA is selectively expressed in striated muscle. Diabetes 50:11 (2001), 2419–2424.
48. [48] Niimi, M., Ogawara, T., Yamashita, T., Yamamoto, Y., Ueyama, A., Kambe, T., Okamoto, T., Ban, T., Tamanoi, H., Ozaki, K., Fujiwara, T., Fukui, H., Takahashi, E.I., Kyushiki, H., Tanigami, A., Identification of GFAT1-L, a novel splice variant of human glutamine: fructose-6-phosphate amidotransferase (GFAT1) that is expressed abundantly in skeletal muscle. J. Hum. Genet. 46:10 (2001), 566–571.
49. [49] Paterson, A.J., Kudlow, J.E., Regulation of glutamine:fructose-6-phosphate amidotransferase gene transcription by epidermal growth factor and glucose. Endocrinology 136:7 (1995), 2809–2816.
50. [50] Chang, Q., Su, K., Baker, J.R., Yang, X., Paterson, A.J., Kudlow, J.E., Phosphorylation of human glutamine:fructose-6-phosphate amidotransferase by cAMP-dependent protein kinase at serine 205 blocks the enzyme activity. J. Biol. Chem. 275:29 (2000), 21981–21987.
51. [51] Hu, Y., Riesland, L., Paterson, A.J., Kudlow, J.E., Phosphorylation of mouse glutamine-fructose-6-phosphate amidotransferase 2 (GFAT2) by cAMP-dependent protein kinase increases the enzyme activity. J. Biol. Chem. 279:29 (2004), 29988–29993.
52. [52] McClain, D.A., Alexander, T., Cooksey, R.C., Considine, R.V., Hexosamines stimulate leptin production in transgenic mice. Endocrinology 141:6 (2000), 1999–2002.
53. [53] Hazel, M., Cooksey, R.C., Jones, D., Parker, G., Neidigh, J.L., Witherbee, B., Gulve, E.A., McClain, D.A., Activation of the hexosamine signaling pathway in adipose tissue results in decreased serum adiponectin and skeletal muscle insulin resistance. Endocrinology 145:5 (2004), 2118–2128.
54. [54] Haltiwanger, R.S., Holt, G.D., Hart, G.W., Enzymatic addition of O-GlcNAc to nuclear and cytoplasmic proteins: identification of a uridine diphospho-N-acetylglucosamine:peptide beta-N-acetylglucosaminyltransferase. J. Biol. Chem. 265:5 (1990), 2563–2568.
55. [55] Haltiwanger, R.S., Blomberg, M.A., Hart, G.W., Glycosylation of nuclear and cytoplasmic proteins: purification and characterization of a uridine diphospho-N-acetylglucosamine:polypeptide beta-N-acetylglucosaminyltransferase. J. Biol. Chem. 267:13 (1992), 9005–9013.
56. [56] Kreppel, L.K., Blomberg, M.A., Hart, G.W., Dynamic glycosylation of nuclear and cytosolic proteins: cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. J. Biol. Chem. 272:14 (1997), 9308–9315.
57. [57] Lubas, W.A., Hanover, J.A., Functional expression of O-linked GlcNAc transferase: domain structure and substrate specificity. J. Biol. Chem. 275:15 (2000), 10983–10988.
58. [58] Capotosti, F., Guernier, S., Lammers, F., Waridel, P., Cai, Y., Jin, J., Conaway, J.W., Conaway, R.C., Herr, W., O-GlcNAc transferase catalyzes site-specific proteolysis of HCF-1. Cell 144:3 (2011), 376–388.
59. [59] Daou, S., Mashtalir, N., Hammond-Martel, I., Pak, H., Yu, H., Sui, G., Vogel, J.L., Kristie, T.M., Affar el, B., Crosstalk between O-GlcNAcylation and proteolytic cleavage regulates the host cell factor-1 maturation pathway. Proc. Natl. Acad. Sci. U. S. A. 108:7 (2011), 2747–2752.
60. [60] Lubas, W.A., Frank, D.W., Krause, M., Hanover, J.A., O-Linked GlcNAc transferase is a conserved nucleocytoplasmic protein containing tetratricopeptide repeats. J. Biol. Chem. 272:14 (1997), 9316–9324.
61. [61] Gao, Y., Wells, L., Comer, F.I., Parker, G.J., Hart, G.W., Dynamic O-glycosylation of nuclear and cytosolic proteins: cloning and characterization of a neutral, cytosolic beta-N-acetylglucosaminidase from human brain. J. Biol. Chem. 276:13 (2001), 9838–9845.
62. [62] Kreppel, L.K., Hart, G.W., Regulation of a cytosolic and nuclear O-GlcNAc transferase: role of the tetratricopeptide repeats. J. Biol. Chem. 274:45 (1999), 32015–32022.
63. [63] Lazarus, M.B., Nam, Y., Jiang, J., Sliz, P., Walker, S., Structure of human O-GlcNAc transferase and its complex with a peptide substrate. Nature 469:7331 (2011), 564–567.
64. [64] Cheung, W.D., Hart, G.W., AMP-activated protein kinase and p38 MAPK activate O-GlcNAcylation of neuronal proteins during glucose deprivation. J. Biol. Chem. 283:19 (2008), 13009–13020.
65. [65] Cheung, W.D., Sakabe, K., Housley, M.P., Dias, W.B., Hart, G.W., O-linked beta-N-acetylglucosaminyltransferase substrate specificity is regulated by myosin phosphatase targeting and other interacting proteins. J. Biol. Chem. 283:49 (2008), 33935–33941.
66. [66] Butkinaree, C., Park, K., Hart, G.W., O-linked beta-N-acetylglucosamine (O-GlcNAc): Extensive crosstalk with phosphorylation to regulate signaling and transcription in response to nutrients and stress. Biochim. Biophys. Acta 1800:2 (2010), 96–106.
67. [67] Fulop, N., Marchase, R.B., Chatham, J.C., Role of protein O-linked N-acetyl-glucosamine in mediating cell function and survival in the cardiovascular system. Cardiovasc. Res. 73:2 (2007), 288–297.
68. [68] Hennebicq-Reig, S., Lesuffleur, T., Capon, C., De Bolos, C., Kim, I., Moreau, O., Richet, C., Hemon, B., Recchi, M.A., Maes, E., Aubert, J.P., Real, F.X., Zweibaum, A., Delannoy, P., Degand, P., Huet, G., Permanent exposure of mucin-secreting HT-29 cells to benzyl-N-acetyl-alpha-D-galactosaminide induces abnormal O-glycosylation of mucins and inhibits constitutive and stimulated MUC5AC secretion. Biochem. J. 334:Part 1 (1998), 283–295.
69. [69] Trapannone, R., Rafie, K., van Aalten, D.M., O-GlcNAc transferase inhibitors: current tools and future challenges. Biochem. Soc. Trans. 44:1 (2016), 88–93.
70. [70] Konrad, R.J., Zhang, F., Hale, J.E., Knierman, M.D., Becker, G.W., Kudlow, J.E., Alloxan is an inhibitor of the enzyme O-linked N-acetylglucosamine transferase. Biochem. Biophys. Res. Commun. 293:1 (2002), 207–212.
71. [71] Liu, K., Paterson, A.J., Chin, E., Kudlow, J.E., Glucose stimulates protein modification by O-linked GlcNAc in pancreatic beta cells: linkage of O-linked GlcNAc to beta cell death. Proc. Natl. Acad. Sci. U. S. A. 97:6 (2000), 2820–2825.
72. [72] Gross, B.J., Kraybill, B.C., Walker, S., Discovery of O-GlcNAc transferase inhibitors. J. Am. Chem. Soc. 127:42 (2005), 14588–14589.
73. [73] Jiang, J., Lazarus, M.B., Pasquina, L., Sliz, P., Walker, S., A neutral diphosphate mimic crosslinks the active site of human O-GlcNAc transferase. Nat. Chem. Biol. 8:1 (2012), 72–77.
74. [74] Banerjee, P.S., Hart, G.W., Cho, J.W., Chemical approaches to study O-GlcNAcylation. Chem. Soc. Rev. 42:10 (2013), 4345–4357.
75. [75] Ngoh, G.A., Watson, L.J., Facundo, H.T., Dillmann, W., Jones, S.P., Non-canonical glycosyltransferase modulates post-hypoxic cardiac myocyte death and mitochondrial permeability transition. J. Mol. Cell. Cardiol. 45:2 (2008), 313–325.
76. [76] Zafir, A., Readnower, R., Long, B.W., McCracken, J., Aird, A., Alvarez, A., Cummins, T.D., Li, Q., Hill, B.G., Bhatnagar, A., Prabhu, S.D., Bolli, R., Jones, S.P., Protein O-GlcNAcylation is a novel cytoprotective signal in cardiac stem cells. Stem Cells 31:4 (2013), 765–775.
77. [77] Gloster, T.M., Zandberg, W.F., Heinonen, J.E., Shen, D.L., Deng, L., Vocadlo, D.J., Hijacking a biosynthetic pathway yields a glycosyltransferase inhibitor within cells. Nat. Chem. Biol. 7:3 (2011), 174–181.
78. [78] Ortiz-Meoz, R.F., Jiang, J., Lazarus, M.B., Orman, M., Janetzko, J., Fan, C., Duveau, D.Y., Tan, Z.W., Thomas, C.J., Walker, S., A small molecule that inhibits OGT activity in cells. ACS Chem. Biol. 10:6 (2015), 1392–1397.
79. [79] McClain, D.A., Lubas, W.A., Cooksey, R.C., Hazel, M., Parker, G.J., Love, D.C., Hanover, J.A., Altered glycan-dependent signaling induces insulin resistance and hyperleptinemia. Proc. Natl. Acad. Sci. U. S. A. 99:16 (2002), 10695–10699.
80. [80] Watson, L.J., Facundo, H.T., Ngoh, G.A., Ameen, M., Brainard, R.E., Lemma, K.M., Long, B.W., Prabhu, S.D., Xuan, Y.T., Jones, S.P., O-linked beta-N-acetylglucosamine transferase is indispensable in the failing heart. Proc. Natl. Acad. Sci. U. S. A. 107:41 (2010), 17797–17802.
81. [81] Comtesse, N., Maldener, E., Meese, E., Identification of a nuclear variant of MGEA5, a cytoplasmic hyaluronidase and a beta-N-acetylglucosaminidase. Biochem. Biophys. Res. Commun. 283:3 (2001), 634–640.
82. [82] Vocadlo, D.J., O-GlcNAc processing enzymes: catalytic mechanisms, substrate specificity, and enzyme regulation. Curr. Opin. Chem. Biol. 16:5–6 (2012), 488–497.
83. [83] Butkinaree, C., Cheung, W.D., Park, S., Park, K., Barber, M., Hart, G.W., Characterization of beta-N-acetylglucosaminidase cleavage by caspase-3 during apoptosis. J. Biol. Chem. 283:35 (2008), 23557–23566.
84. [84] Schimpl, M., Schuttelkopf, A.W., Borodkin, V.S., van Aalten, D.M., Human OGA binds substrates in a conserved peptide recognition groove. Biochem. J 432:1 (2010), 1–7.
85. [85] Schimpl, M., Borodkin, V.S., Gray, L.J., van Aalten, D.M., Synergy of peptide and sugar in O-GlcNAcase substrate recognition. Chem. Biol. 19:2 (2012), 173–178.
86. [86] Lameira, J., Alves, C.N., Moliner, V., Marti, S., Kanaan, N., Tunon, I., A quantum mechanics/molecular mechanics study of the protein-ligand interaction of two potent inhibitors of human O-GlcNAcase: pUGNAc and NAG-thiazoline. J. Phys. Chem. B 112:45 (2008), 14260–14266.
87. [87] Yuzwa, S.A., Macauley, M.S., Heinonen, J.E., Shan, X., Dennis, R.J., He, Y., Whitworth, G.E., Stubbs, K.A., McEachern, E.J., Davies, G.J., Vocadlo, D.J., A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat. Chem. Biol. 4:8 (2008), 483–490.
88. [88] Laczy, B., Marsh, S.A., Brocks, C.A., Wittmann, I., Chatham, J.C., Inhibition of O-GlcNAcase in perfused rat hearts by NAG-thiazolines at the time of reperfusion is cardioprotective in an O-GlcNAc-dependent manner. Am. J. Physiol. Heart Circ. Physiol. 299:5 (2010), H1715–1727.
89. [89] Shanmugasundaram, B., Debowski, A.W., Dennis, R.J., Davies, G.J., Vocadlo, D.J., Vasella, A., Inhibition of O-GlcNAcase by a gluco-configured nagstatin and a PUGNAc-imidazole hybrid inhibitor. Chem. Commun. (Camb). 42 (2006), 4372–4374.
90. [90] Whitworth, G.E., Macauley, M.S., Stubbs, K.A., Dennis, R.J., Taylor, E.J., Davies, G.J., Greig, I.R., Vocadlo, D.J., Analysis of PUGNAc and NAG-thiazoline as transition state analogues for human O-GlcNAcase: mechanistic and structural insights into inhibitor selectivity and transition state poise. J. Am. Chem. Soc. 129:3 (2007), 635–644.
91. [91] Dehennaut, V., Lefebvre, T., Proteomics and PUGNAcity will overcome questioning of insulin resistance induction by nonselective inhibition of O-GlcNAcase. Proteomics 13:20 (2013), 2944–2946.
92. [92] Champattanachai, V., Marchase, R.B., Chatham, J.C., Glucosamine protects neonatal cardiomyocytes from ischemia-reperfusion injury via increased protein-associated O-GlcNAc. Am. J. Physiol. Cell Physiol. 292:1 (2007), C178–187.
93. [93] Jones, S.P., Zachara, N.E., Ngoh, G.A., Hill, B.G., Teshima, Y., Bhatnagar, A., Hart, G.W., Marban, E., Cardioprotection by N-acetylglucosamine linkage to cellular proteins. Circulation 117:9 (2008), 1172–1182.
94. [94] Zou, L., Yang, S., Hu, S., Chaudry, I.H., Marchase, R.B., Chatham, J.C., The protective effects of PUGNAc on cardiac function after trauma-hemorrhage are mediated via increased protein O-GlcNAc levels. Shock 27:4 (2007), 402–408.
95. [95] Lee, J.E., Park, J.H., Moon, P.G., Baek, M.C., Identification of differentially expressed proteins by treatment with PUGNAc in 3T3-L1 adipocytes through analysis of ATP-binding proteome. Proteomics 13:20 (2013), 2998–3012.
96. [96] Macauley, M.S., Bubb, A.K., Martinez-Fleites, C., Davies, G.J., Vocadlo, D.J., Elevation of global O-GlcNAc levels in 3T3-L1 adipocytes by selective inhibition of O-GlcNAcase does not induce insulin resistance. J. Biol. Chem. 283:50 (2008), 34687–34695.
97. [97] Macauley, M.S., Shan, X., Yuzwa, S.A., Gloster, T.M., Vocadlo, D.J., Elevation of Global O-GlcNAc in rodents using a selective O-GlcNAcase inhibitor does not cause insulin resistance or perturb glucohomeostasis. Chem. Biol. 17:9 (2010), 949–958.
98. [98] Dorfmueller, H.C., Borodkin, V.S., Schimpl, M., Shepherd, S.M., Shpiro, N.A., van Aalten, D.M., GlcNAcstatin: a picomolar, selective O-GlcNAcase inhibitor that modulates intracellular O-glcNAcylation levels. J. Am. Chem. Soc. 128:51 (2006), 16484–16485.
99. [99] Dorfmueller, H.C., Borodkin, V.S., Schimpl, M., Zheng, X., Kime, R., Read, K.D., van Aalten, D.M., Cell-penetrant, nanomolar O-GlcNAcase inhibitors selective against lysosomal hexosaminidases. Chem. Biol. 17:11 (2010), 1250–1255.
100. [100] Ngoh, G.A., Hamid, T., Prabhu, S.D., Jones, S.P., O-GlcNAc signaling attenuates ER stress-induced cardiomyocyte death. Am. J. Physiol. Heart Circ. Physiol. 297:5 (2009), H1711–1719.
101. [101] Roos, M.D., Xie, W., Su, K., Clark, J.A., Yang, X., Chin, E., Paterson, A.J., Kudlow, J.E., Streptozotocin, an analog of N-acetylglucosamine, blocks the removal of O-GlcNAc from intracellular proteins. Proc. Assoc. Am. Phys. 110:5 (1998), 422–432.
102. [102] Hanover, J.A., Lai, Z., Lee, G., Lubas, W.A., Sato, S.M., Elevated O-linked N-acetylglucosamine metabolism in pancreatic beta-cells. Arch. Biochem. Biophys. 362:1 (1999), 38–45.
103. [103] Gao, Y., Parker, G.J., Hart, G.W., Streptozotocin-induced beta-cell death is independent of its inhibition of O-GlcNAcase in pancreatic Min6 cells. Arch. Biochem. Biophys. 383:2 (2000), 296–302.
104. [104] Okuyama, R., Yachi, M., Cytosolic O-GlcNAc accumulation is not involved in beta-cell death in HIT-T15 or Min6. Biochem. Biophys. Res. Commun. 287:2 (2001), 366–371.
105. [105] Ngoh, G.A., Watson, L.J., Facundo, H.T., Jones, S.P., Augmented O-GlcNAc signaling attenuates oxidative stress and calcium overload in cardiomyocytes. Amino Acids 40:3 (2011), 895–911.
106. [106] Hart, G.W., Kreppel, L.K., Comer, F.I., Arnold, C.S., Snow, D.M., Ye, Z., Cheng, X., DellaManna, D., Caine, D.S., Earles, B.J., Akimoto, Y., Cole, R.N., Hayes, B.K., O-GlcNAcylation of key nuclear and cytoskeletal proteins: reciprocity with O-phosphorylation and putative roles in protein multimerization. Glycobiology 6:7 (1996), 711–716.
107. [107] Wang, Z., Pandey, A., Hart, G.W., Dynamic interplay between O-linked N-acetylglucosaminylation and glycogen synthase kinase-3-dependent phosphorylation. Mol. Cell. Proteomics 6:8 (2007), 1365–1379.
108. [108] Griffith, L.S., Schmitz, B., O-linked N-acetylglucosamine levels in cerebellar neurons respond reciprocally to pertubations of phosphorylation. Eur. J. Biochem. 262:3 (1999), 824–831.
109. [109] Wang, Z., Gucek, M., Hart, G.W., Cross-talk between GlcNAcylation and phosphorylation: site-specific phosphorylation dynamics in response to globally elevated O-GlcNAc. Proc. Natl. Acad. Sci. U. S. A. 105:37 (2008), 13793–13798.
110. [110] Medina, L., Grove, K., Haltiwanger, R.S., SV40 large T antigen is modified with O-linked N-acetylglucosamine but not with other forms of glycosylation. Glycobiology 8:4 (1998), 383–391.
111. [111] Cheng, X., Cole, R.N., Zaia, J., Hart, G.W., Alternative O-glycosylation/O-phosphorylation of the murine estrogen receptor beta. Biochemistry 39:38 (2000), 11609–11620.
112. [112] Kamemura, K., Hayes, B.K., Comer, F.I., Hart, G.W., Dynamic interplay between O-glycosylation and O-phosphorylation of nucleocytoplasmic proteins: alternative glycosylation/phosphorylation of THR-58, a known mutational hot spot of c-Myc in lymphomas, is regulated by mitogens. J. Biol. Chem. 277:21 (2002), 19229–19235.
113. [113] Cole, R.N., Hart, G.W., Glycosylation sites flank phosphorylation sites on synapsin I: O-linked N-acetylglucosamine residues are localized within domains mediating synapsin I interactions. J. Neurochem. 73:1 (1999), 418–428.
114. [114] Kelly, W.G., Dahmus, M.E., Hart, G.W., RNA polymerase II is a glycoprotein: modification of the COOH-terminal domain by O-GlcNAc. J. Biol. Chem. 268:14 (1993), 10416–10424.
115. [115] Comer, F.I., Hart, G.W., Reciprocity between O-GlcNAc and O-phosphate on the carboxyl terminal domain of RNA polymerase II. Biochemistry 40:26 (2001), 7845–7852.
116. [116] Chou, C.F., Smith, A.J., Omary, M.B., Characterization and dynamics of O-linked glycosylation of human cytokeratin 8 and 18. J. Biol. Chem. 267:6 (1992), 3901–3906.
117. [117] Arnold, C.S., Johnson, G.V., Cole, R.N., Dong, D.L., Lee, M., Hart, G.W., The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine. J. Biol. Chem. 271:46 (1996), 28741–28744.
118. [118] O'Donnell, N., Zachara, N.E., Hart, G.W., Marth, J.D., Ogt-dependent X-chromosome-linked protein glycosylation is a requisite modification in somatic cell function and embryo viability. Mol. Cell. Biol. 24:4 (2004), 1680–1690.
119. [119] Gong, C.X., Liu, F., Grundke-Iqbal, I., Iqbal, K., Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation. J. Alzheimers Dis. 9:1 (2006), 1–12.
120. [120] Chatham, J.C., Marchase, R.B., The role of protein O-linked beta-N-acetylglucosamine in mediating cardiac stress responses. Biochim. Biophys. Acta 1800:2 (2010), 57–66.
121. [121] Facundo, H.T., Brainard, R.E., Watson, L.J., Ngoh, G.A., Hamid, T., Prabhu, S.D., Jones, S.P., O-GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 302:10 (2012), H2122–2130.
122. [122] Abe, T., Ohga, Y., Tabayashi, N., Kobayashi, S., Sakata, S., Misawa, H., Tsuji, T., Kohzuki, H., Suga, H., Taniguchi, S., Takaki, M., Left ventricular diastolic dysfunction in type 2 diabetes mellitus model rats. Am. J. Physiol. Heart Circ. Physiol. 282:1 (2002), H138–148.
123. [123] Liu, J., Marchase, R.B., Chatham, J.C., Glutamine-induced protection of isolated rat heart from ischemia/reperfusion injury is mediated via the hexosamine biosynthesis pathway and increased protein O-GlcNAc levels. J. Mol. Cell Cardiol. 42:1 (2007), 177–185.
124. [124] Yang, S., Zou, L.Y., Bounelis, P., Chaudry, I., Chatham, J.C., Marchase, R.B., Glucosamine administration during resuscitation improves organ function after trauma hemorrhage. Shock 25:6 (2006), 600–607.
125. [125] Champattanachai, V., Marchase, R.B., Chatham, J.C., Glucosamine protects neonatal cardiomyocytes from ischemia-reperfusion injury via increased protein O-GlcNAc and increased mitochondrial Bcl-2. Am. J. Physiol. Cell Physiol. 294:6 (2008), C1509–1520.
126. [126] Zou, L., Yang, S., Champattanachai, V., Hu, S., Chaudry, I.H., Marchase, R.B., Chatham, J.C., Glucosamine improves cardiac function following trauma-hemorrhage by increased protein O-GlcNAcylation and attenuation of NF-{kappa}B signaling. Am. J. Physiol. Heart Circ. Physiol. 296:2 (2009), H515–523.
127. [127] Srinivasan, V., Sandhya, N., Sampathkumar, R., Farooq, S., Mohan, V., Balasubramanyam, M., Glutamine fructose-6-phosphate amidotransferase (GFAT) gene expression and activity in patients with type 2 diabetes: inter-relationships with hyperglycaemia and oxidative stress. Clin. Biochem. 40:13–14 (2007), 952–957.
128. [128] Yki-Jarvinen, H., Daniels, M.C., Virkamaki, A., Makimattila, S., DeFronzo, R.A., McClain, D., Increased glutamine:fructose-6-phosphate amidotransferase activity in skeletal muscle of patients with NIDDM. Diabetes 45:3 (1996), 302–307.
129. [129] Lehman, D.M., Fu, D.J., Freeman, A.B., Hunt, K.J., Leach, R.J., Johnson-Pais, T., Hamlington, J., Dyer, T.D., Arya, R., Abboud, H., Goring, H.H., Duggirala, R., Blangero, J., Konrad, R.J., Stern, M.P., A single nucleotide polymorphism in MGEA5 encoding O-GlcNAc-selective N-acetyl-beta-D glucosaminidase is associated with type 2 diabetes in Mexican Americans. Diabetes 54:4 (2005), 1214–1221.
130. [130] Akimoto, Y., Kreppel, L.K., Hirano, H., Hart, G.W., Increased O-GlcNAc transferase in pancreas of rats with streptozotocin-induced diabetes. Diabetologia 43:10 (2000), 1239–1247.
131. [131] Akimoto, Y., Kreppel, L.K., Hirano, H., Hart, G.W., Hyperglycemia and the O-GlcNAc transferase in rat aortic smooth muscle cells: elevated expression and altered patterns of O-GlcNAcylation. Arch. Biochem. Biophys. 389:2 (2001), 166–175.
132. [132] Buse, M.G., Robinson, K.A., Marshall, B.A., Hresko, R.C., Mueckler, M.M., Enhanced O-GlcNAc protein modification is associated with insulin resistance in GLUT1-overexpressing muscles. Am. J. Physiol. Endocrinol. Metab. 283:2 (2002), E241–250.
133. [133] Fulop, N., Mason, M.M., Dutta, K., Wang, P., Davidoff, A.J., Marchase, R.B., Chatham, J.C., Impact of Type 2 diabetes and aging on cardiomyocyte function and O-linked N-acetylglucosamine levels in the heart. Am. J. Physiol. Cell Physiol. 292:4 (2007), C1370–1378.
134. [134] Hu, Y., Suarez, J., Fricovsky, E., Wang, H., Scott, B.T., Trauger, S.A., Han, W., Hu, Y., Oyeleye, M.O., Dillmann, W.H., Increased enzymatic O-GlcNAcylation of mitochondrial proteins impairs mitochondrial function in cardiac myocytes exposed to high glucose. J. Biol. Chem. 284:1 (2009), 547–555.
135. [135] Marsh, S.A., Dell'italia, L.J., Chatham, J.C., Interaction of diet and diabetes on cardiovascular function in rats. Am. J. Physiol. Heart Circ. Physiol. 296:2 (2009), H282–292.
136. [136] Wang, Z., Park, K., Comer, F., Hsieh-Wilson, L.C., Saudek, C.D., Hart, G.W., Site-specific GlcNAcylation of human erythrocyte proteins: potential biomarker(s) for diabetes. Diabetes 58:2 (2009), 309–317.
137. [137] Lebeche, D., Davidoff, A.J., Hajjar, R.J., Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy. Nat. Clin. Pract. Cardiovasc. Med. 5:11 (2008), 715–724.
138. [138] Rajamani, U., Essop, M.F., Hyperglycemia-mediated activation of the hexosamine biosynthetic pathway results in myocardial apoptosis. Am. J. Physiol. Cell Physiol. 299:1 (2010), C139–147.
139. [139] Nerlich, A.G., Sauer, U., Kolm-Litty, V., Wagner, E., Koch, M., Schleicher, E.D., Expression of glutamine:fructose-6-phosphate amidotransferase in human tissues: evidence for high variability and distinct regulation in diabetes. Diabetes 47:2 (1998), 170–178.
140. [140] Clark, R.J., McDonough, P.M., Swanson, E., Trost, S.U., Suzuki, M., Fukuda, M., Dillmann, W.H., Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. J. Biol. Chem. 278:45 (2003), 44230–44237.
141. [141] Hu, Y., Belke, D., Suarez, J., Swanson, E., Clark, R., Hoshijima, M., Dillmann, W.H., Adenovirus-mediated overexpression of O-GlcNAcase improves contractile function in the diabetic heart. Circ. Res. 96:9 (2005), 1006–1013.
142. [142] Fiordaliso, F., Leri, A., Cesselli, D., Limana, F., Safai, B., Nadal-Ginard, B., Anversa, P., Kajstura, J., Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death. Diabetes 50:10 (2001), 2363–2375.
143. [143] Ma, J., Banerjee, P.S., Whelan, S.A., Liu, T., Wei, A.C., Ramirez-Correa, G., McComb, M.E., Costello, C.E., O'Rourke, B., Murphy, A., Hart, G.W., Comparative proteomics reveals dysregulated mitochondrial O-GlcNAcylation in diabetic hearts. J. Proteome Res. 15:7 (2016), 2254–2264.
144. [144] Liu, K., Paterson, A.J., Konrad, R.J., Parlow, A.F., Jimi, S., Roh, M., Chin, E. Jr., Kudlow, J.E., Streptozotocin, an O-GlcNAcase inhibitor, blunts insulin and growth hormone secretion. Mol. Cell Endocrinol. 194:1–2 (2002), 135–146.
145. [145] Ren, J., Davidoff, A.J., Diabetes rapidly induces contractile dysfunctions in isolated ventricular myocytes. Am. J. Physiol. 272:1 Pt 2 (1997), H148–158.
146. [146] Davidoff, A.J., Ren, J., Low insulin and high glucose induce abnormal relaxation in cultured adult rat ventricular myocytes. Am. J. Physiol. 272:1 Pt 2 (1997), H159–167.
147. [147] Dutta, K., Carmody, M.W., Cala, S.E., Davidoff, A.J., Depressed PKA activity contributes to impaired SERCA function and is linked to the pathogenesis of glucose-induced cardiomyopathy. J. Mol. Cell Cardiol. 34:8 (2002), 985–996.
148. [148] Dutta, K., Podolin, D.A., Davidson, M.B., Davidoff, A.J., Cardiomyocyte dysfunction in sucrose-fed rats is associated with insulin resistance. Diabetes 50:5 (2001), 1186–1192.
149. [149] Wold, L.E., Dutta, K., Mason, M.M., Ren, J., Cala, S.E., Schwanke, M.L., Davidoff, A.J., Impaired SERCA function contributes to cardiomyocyte dysfunction in insulin resistant rats. J. Mol. Cell. Cardiol. 39:2 (2005), 297–307.
150. [150] Belke, D.D., Swanson, E.A., Dillmann, W.H., Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart. Diabetes 53:12 (2004), 3201–3208.
151. [151] Choi, K.M., Zhong, Y., Hoit, B.D., Grupp, I.L., Hahn, H., Dilly, K.W., Guatimosim, S., Lederer, W.J., Matlib, M.A., Defective intracellular Ca(2 + ) signaling contributes to cardiomyopathy in Type 1 diabetic rats. Am. J. Physiol. Heart Circ. Physiol. 283:4 (2002), H1398–1408.
152. [152] Lacombe, V.A., Viatchenko-Karpinski, S., Terentyev, D., Sridhar, A., Emani, S., Bonagura, J.D., Feldman, D.S., Gyorke, S., Carnes, C.A., Mechanisms of impaired calcium handling underlying subclinical diastolic dysfunction in diabetes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293:5 (2007), R1787–1797.
153. [153] Armoundas, A.A., Rose, J., Aggarwal, R., Stuyvers, B.D., O'Rourke, B., Kass, D.A., Marban, E., Shorofsky, S.R., Tomaselli, G.F., William Balke, C., Cellular and molecular determinants of altered Ca2+ handling in the failing rabbit heart: primary defects in SR Ca2+ uptake and release mechanisms. Am. J. Physiol. Heart Circ. Physiol. 292:3 (2007), H1607–1618.
154. [154] Currie, S., Smith, G.L., Enhanced phosphorylation of phospholamban and downregulation of sarco/endoplasmic reticulum Ca2+ ATPase type 2 (SERCA 2) in cardiac sarcoplasmic reticulum from rabbits with heart failure. Cardiovasc. Res. 41:1 (1999), 135–146.
155. [155] Schaffer, S.W., Mozaffari, M.S., Artman, M., Wilson, G.L., Basis for myocardial mechanical defects associated with non-insulin-dependent diabetes. Am. J. Physiol. 256:1 Pt 1 (1989), E25–30.
156. [156] Depre, C., Young, M.E., Ying, J., Ahuja, H.S., Han, Q., Garza, N., Davies, P.J., Taegtmeyer, H., Streptozotocin-induced changes in cardiac gene expression in the absence of severe contractile dysfunction. J. Mol. Cell Cardiol. 32:6 (2000), 985–996.
157. [157] Hofmann, P.A., Menon, V., Gannaway, K.F., Effects of diabetes on isometric tension as a function of [Ca2 + ] and pH in rat skinned cardiac myocytes. Am. J. Physiol. 269:5 Pt 2 (1995), H1656–1663.
158. [158] Ishikawa, T., Kajiwara, H., Kurihara, S., Alterations in contractile properties and Ca2+ handling in streptozotocin-induced diabetic rat myocardium. Am. J. Physiol. 277:6 Pt 2 (1999), H2185–2194.
159. [159] Hedou, J., Cieniewski-Bernard, C., Leroy, Y., Michalski, J.C., Mounier, Y., Bastide, B., O-linked N-acetylglucosaminylation is involved in the Ca2+ activation properties of rat skeletal muscle. J. Biol. Chem. 282:14 (2007), 10360–10369.
160. [160] Hoshijima, M., Mechanical stress-strain sensors embedded in cardiac cytoskeleton: z disk, titin, and associated structures. Am. J. Physiol. Heart Circ. Physiol. 290:4 (2006), H1313–1325.
161. [161] Ramirez-Correa, G.A., Jin, W., Wang, Z., Zhong, X., Gao, W.D., Dias, W.B., Vecoli, C., Hart, G.W., Murphy, A.M., O-linked GlcNAc modification of cardiac myofilament proteins: a novel regulator of myocardial contractile function. Circ. Res. 103:12 (2008), 1354–1358.
162. [162] Dillmann, W.H., Diabetes mellitus and hypothyroidism induce changes in myosin isoenzyme distribution in the rat heart–do alterations in fuel flux mediate these changes?. Adv. Exp. Med. Biol. 194 (1986), 469–479.
163. [163] Li, S.Y., Yang, X., Ceylan-Isik, A.F., Du, M., Sreejayan, N., Ren, J., Cardiac contractile dysfunction in Lep/Lep obesity is accompanied by NADPH oxidase activation, oxidative modification of sarco(endo)plasmic reticulum Ca2+-ATPase and myosin heavy chain isozyme switch. Diabetologia 49:6 (2006), 1434–1446.
164. [164] Yokoe, S., Asahi, M., Takeda, T., Otsu, K., Taniguchi, N., Miyoshi, E., Suzuki, K., Inhibition of phospholamban phosphorylation by O-GlcNAcylation: implications for diabetic cardiomyopathy. Glycobiology 20:10 (2010), 1217–1226.
165. [165] Pang, Y., Hunton, D.L., Bounelis, P., Marchase, R.B., Hyperglycemia inhibits capacitative calcium entry and hypertrophy in neonatal cardiomyocytes. Diabetes 51:12 (2002), 3461–3467.
166. [166] Zou, L., Zhu-Mauldin, X., Marchase, R.B., Paterson, A.J., Liu, J., Yang, Q., Chatham, J.C., Glucose deprivation-induced increase in protein O-GlcNAcylation in cardiomyocytes is calcium-dependent. J. Biol. Chem. 287:41 (2012), 34419–34431.
167. [167] Bell, J.R., Raaijmakers, A.J., Janssens, J.V., Delbridge, L.M., CaMKIIdelta and cardiomyocyte Ca(2 + ) signalling new perspectives on splice variant targeting. Clin. Exp. Pharmacol. Physiol. 42:12 (2015), 1327–1332.
168. [168] Erickson, J.R., Pereira, L., Wang, L., Han, G., Ferguson, A., Dao, K., Copeland, R.J., Despa, F., Hart, G.W., Ripplinger, C.M., Bers, D.M., Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. Nature 502:7471 (2013), 372–376.
169. [169] Daniels, L., Bell, J.R., Delbridge, L.M., McDonald, F.J., Lamberts, R.R., Erickson, J.R., The role of CaMKII in diabetic heart dysfunction. Heart Failure Rev. 20:5 (2015), 589–600.
170. [170] Sommese, L., Valverde, C.A., Blanco, P., Castro, M.C., Rueda, O.V., Kaetzel, M., Dedman, J., Anderson, M.E., Mattiazzi, A., Palomeque, J., Ryanodine receptor phosphorylation by CaMKII promotes spontaneous Ca(2 + ) release events in a rodent model of early stage diabetes: the arrhythmogenic substrate. Int. J. Cardiol. 202 (2016), 394–406.
171. [171] Luo, M., Guan, X., Luczak, E.D., Lang, D., Kutschke, W., Gao, Z., Yang, J., Glynn, P., Sossalla, S., Swaminathan, P.D., Weiss, R.M., Yang, B., Rokita, A.G., Maier, L.S., Efimov, I.R., Hund, T.J., Anderson, M.E., Diabetes increases mortality after myocardial infarction by oxidizing CaMKII. J. Clin. Invest. 123:3 (2013), 1262–1274.
172. [172] Wu, Y., Anderson, M.E., CaMKII in sinoatrial node physiology and dysfunction. Front. Pharmacol., 5, 2014, 48.
173. [173] Pang, Y., Bounelis, P., Chatham, J.C., Marchase, R.B., Hexosamine pathway is responsible for inhibition by diabetes of phenylephrine-induced inotropy. Diabetes 53:4 (2004), 1074–1081.
174. [174] Nagy, T., Champattanachai, V., Marchase, R.B., Chatham, J.C., Glucosamine inhibits angiotensin II-induced cytoplasmic Ca2+ elevation in neonatal cardiomyocytes via protein-associated O-linked N-acetylglucosamine. Am. J. Physiol. Cell Physiol. 290:1 (2006), C57–65.
175. [175] Kim, Y.H., Song, M., Oh, Y.S., Heo, K., Choi, J.W., Park, J.M., Kim, S.H., Lim, S., Kwon, H.M., Ryu, S.H., Suh, P.G., Inhibition of phospholipase C-beta1-mediated signaling by O-GlcNAc modification. J. Cell. Physiol. 207:3 (2006), 689–696.
176. [176] Zhu-Mauldin, X., Marsh, S.A., Zou, L., Marchase, R.B., Chatham, J.C., Modification of STIM1 by O-linked N-acetylglucosamine (O-GlcNAc) attenuates store-operated calcium entry in neonatal cardiomyocytes. J. Biol. Chem. 287:46 (2012), 39094–39106.
177. [177] Marsh, S.A., Dell'Italia, L.J., Chatham, J.C., Activation of the hexosamine biosynthesis pathway and protein O-GlcNAcylation modulate hypertrophic and cell signaling pathways in cardiomyocytes from diabetic mice. Amino Acids 40:3 (2011), 819–828.
178. [178] Asbun, J., Manso, A.M., Villarreal, F.J., Profibrotic influence of high glucose concentration on cardiac fibroblast functions: effects of losartan and vitamin E. Am. J. Physiol. Heart Circ. Physiol. 288:1 (2005), H227–234.
179. [179] James, L.R., Tang, D., Ingram, A., Ly, H., Thai, K., Cai, L., Scholey, J.W., Flux through the hexosamine pathway is a determinant of nuclear factor kappaB- dependent promoter activation. Diabetes 51:4 (2002), 1146–1156.
180. [180] James, L.R., Fantus, I.G., Goldberg, H., Ly, H., Scholey, J.W., Overexpression of GFAT activates PAI-1 promoter in mesangial cells. Am. J. Physiol. Renal Physiol. 279:4 (2000), F718–727.
181. [181] Kolm-Litty, V., Sauer, U., Nerlich, A., Lehmann, R., Schleicher, E.D., High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J. Clin. Invest. 101:1 (1998), 160–169.
182. [182] Neumann, S., Huse, K., Semrau, R., Diegeler, A., Gebhardt, R., Buniatian, G.H., Scholz, G.H., Aldosterone and D-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro. Hypertension 39:3 (2002), 756–760.
183. [183] Tokudome, T., Horio, T., Yoshihara, F., Suga, S., Kawano, Y., Kohno, M., Kangawa, K., Direct effects of high glucose and insulin on protein synthesis in cultured cardiac myocytes and DNA and collagen synthesis in cardiac fibroblasts. Metabolism 53:6 (2004), 710–715.
184. [184] Goldberg, H., Whiteside, C., Fantus, I.G., O-linked beta-N-acetylglucosamine supports p38 MAPK activation by high glucose in glomerular mesangial cells. Am. J. Physiol. Endocrinol. Metab. 301:4 (2011), E713–726.
185. [185] Lima, V.V., Spitler, K., Choi, H., Webb, R.C., Tostes, R.C., O-GlcNAcylation and oxidation of proteins: is signalling in the cardiovascular system becoming sweeter?. Clin. Sci. (Lond) 123:8 (2012), 473–486.
186. [186] Du, X.L., Edelstein, D., Dimmeler, S., Ju, Q., Sui, C., Brownlee, M., Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J. Clin. Invest. 108:9 (2001), 1341–1348.
187. [187] Du, X.L., Edelstein, D., Rossetti, L., Fantus, I.G., Goldberg, H., Ziyadeh, F., Wu, J., Brownlee, M., Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc. Natl. Acad. Sci. U. S. A. 97:22 (2000), 12222–12226.
188. [188] Thum, T., Fraccarollo, D., Schultheiss, M., Froese, S., Galuppo, P., Widder, J.D., Tsikas, D., Ertl, G., Bauersachs, J., Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes 56:3 (2007), 666–674.
189. [189] Gutierrez, J., Ballinger, S.W., Darley-Usmar, V.M., Landar, A., Free radicals, mitochondria, and oxidized lipids: the emerging role in signal transduction in vascular cells. Circ. Res. 99:9 (2006), 924–932.
190. [190] Shin, S.H., Love, D.C., Hanover, J.A., Elevated O-GlcNAc-dependent signaling through inducible mOGT expression selectively triggers apoptosis. Amino Acids 40:3 (2011), 885–893.
191. [191] Du, X., Matsumura, T., Edelstein, D., Rossetti, L., Zsengeller, Z., Szabo, C., Brownlee, M., Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J. Clin. Invest. 112:7 (2003), 1049–1057.